Pembrolizumab + carboplatin + pemetrexed (NSCLC non-squamous, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-PEMBROLIZUMAB` `DRUG-CARBOPLATIN` `DRUG-PEMETREXED`

ID	`REG-PEMBRO-CHEMO-NSCLC-NONSQ`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-NCCN-NSCLC-2025`

Notes

KEYNOTE-189: superior OS in non-sq NSCLC 1L driver-negative regardless of PD-L1 status. NOTE: DRUG-PEMETREXED not yet in KB — placeholder reference; if pemetrexed YAML missing this regimen will surface ref-error. Will be created in cross-disease drug pass.

Used By

Handbook Chapters

HB-NSCLC-METASTATIC-1L - Metastatic NSCLC: driver-first treatment reasoning

Indication

IND-NSCLC-PDL1-LOW-NONSQ-MET-1L - IND-NSCLC-PDL1-LOW-NONSQ-MET-1L